#NORML #News Source: @norml @WeedConnection Posted By: email@example.com media :: news - Tue, 03 Dec 2019 04:20:21 PST
Cannabis Descheduling Bill Passed by Key Congressional Committee
The Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act
Washington, DC: Members of the United States House Judiciary Committee on Wednesday passed legislation – House Bill 3884: The Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act – by more than a two-to-one margin.
Members decided 24 to 10 in favor of the Act, with two Republicans voting in support of the bill. The MORE Act removes the marijuana plant from the federal Controlled Substances Act, thereby enabling states to enact their own cannabis regulations free from undue federal interference. The vote marks the first time that members of Congress have ever voted to federally deschedule cannabis.
The Act also provides for the review and expungement of past cannabis convictions and provides reinvestments to those communities most adversely impacted by the drug war. It also prohibits the denial of federal aid to those who use cannabis in compliance with state law and allows physicians affiliated with the US Veterans Administration to authorize medical cannabis recommendations, among other changes. The measure is the most comprehensive piece of marijuana-related legislation ever approved by a body of Congress.
House Judiciary Chairman Jerrold Nadler, who sponsored the bill, said: "States have led the way and continue to lead the way, but our federal laws have not kept pace with the obvious need for change. We need to catch up because of public support [in favor of legalizing marijuana] and because it is the right thing to do."
NORML's Political Director Justin Strekal praised the House Judiciary vote, stating, "Not only does this bill reverse the failed prohibition of cannabis, but it also provides pathways for opportunity and ownership in the emerging industry for those who have suffered the most under federal criminalization."
Chairman Nadler indicated that the next stop for the More Act could be a House floor vote, presuming that other committee chairs agree to waive their jurisdiction over the bill.
Study: Inhaled Cannabis Associated with Reductions in Migraine Severity
Pullman, WA: Cannabis inhalation is associated with self-reported reductions in headache and migraine severity, according to clinical data published in the Journal of Pain.
A team of investigators from Washington State University reviewed archived data from 1,959 anonymous cannabis consumers who tracked their cannabis use and headache frequency over a 16-month period via an online application.
Authors reported that inhaled cannabis reduced subjects' perceived severity of headache and migraine by nearly 50 percent. Men were more likely than women to report changes in headache severity.
Investigators also acknowledged that many subjects exhibited tolerance to cannabis over time, as they required increased quantities to maintain the same self-reported analgesic effects.
They concluded: "The present study indicates that inhaled cannabis reduces headache and migraine severity ratings by approximately 50 percent. Repeated use of cannabis is associated with tolerance to its effects, making tolerance a risk factor for the use of cannabis to treat headache and migraine. However, cannabis does not lead to the medication overuse headache that is associated with other conventional treatments, meaning that use of cannabis does not make headaches or migraines worse over time. Future double-blind, placebo-controlled clinical trials are warranted and will help to rule out placebo effects and provide a more controlled examination of dose, type of cannabis, THC, CBD, and THC x CBD interactions."
Full text of the study, "Short and Long-term effects of cannabis on headaches and migraine," appears in the Journal of Pain.
Poll: Two-Thirds of Americans Believe "Marijuana Should Be Made Legal"
Washington, DC: More than two out of three US adults believe that the personal use of cannabis should be legal, according to nationwide polling data compiled by the Pew Research Center.
Sixty-seven percent of respondents said that the "use of marijuana should be made legal." That is the highest percentage of support ever recorded by Pew, which has been surveying Americans' attitudes on marijuana policy since 1969. Public support for legalization has more than doubled in the past decade.
The Pew survey is the fourth national poll released in recent weeks showing majority support for cannabis legalization. Recently compiled polling data by Gallup and the Public Religion Research Institute both reported that two-thirds of Americans endorse legalization, while survey data compiled by Harvard reported that 62 percent of US adults back the policy change.
Consistent with other national surveys, support for adult-use legalization was strongest among self-identified Democrats (78 percent) and Millennials (76 percent), but was weaker among Republicans (55 percent) and those born before 1945 (35 percent).
"The percentage of the public who favors adult-use marijuana legalization has skyrocketed over the past three decades and shows no signs of abating," NORML Executive Director Erik Altieri said. "As more and more states have moved forward with their own marijuana liberalization policies in recent years, public support has only grown stronger. At a time when political divides are larger than ever, the issue of marijuana legalization is one of the few policy issues upon which most Americans agree."
Study: CBD Administration Associated with Reduced Opioid Use in Chronic Pain Patients
Louisville, KY: The administration of CBD-rich soft-gel capsules is associated with reduced opioid intake and improved quality of life in chronic pain patients, according to clinical trial data in the journal Postgraduate Medicine.
Investigators from the University of Louisville in Kentucky and The Lambert Center for the Study of Medicinal Cannabis and Hemp at Thomas Jefferson University in Philadelphia assessed the use of plant-derived, standardized CBD-dominant oral extracts (15.7mgs CBD and 0.5mgs THC) in pain patients over an eight-week period. Most participants consumed two soft gels daily over the course of the study.
Of those participants who completed the trial, 53 percent reduced their use of opioids. Ninety-four percent of subjects reported improvements in their quality of life, including reductions in pain and improved sleep.
Researchers reported: "This study concludes that using CBD for chronic pain in patients using opioids has a significant effect on reducing opioid intake, reducing pain and improving QoL (quality of life). Over half of the participants who added CBD hemp extract reduced or eliminated opioids over the course of 8 weeks, and almost all CBD users reported improvements in QoL. … This is consistent with emerging literature on the topic, which has concluded that CBD is an effective analgesic, and one that helps reduce barriers to opioid reduction, such as physiological withdrawal symptoms."
Numerous prior studies – such as those here and here – have similarly demonstrated that pain patients typically mitigate or eliminate their use of opioid drugs after initiating medical cannabis therapy.
Full text of the study, "Evaluations of effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study," appears in Postgraduate Medicine.
Michigan: Adult-Use Marijuana Sales to Begin This December
Lansing, MI: Select retailers will begin engaging in adult-use marijuana sales next month according to an advisory issued by the Michigan Marijuana Regulatory Agency.
Beginning on December 1, state-licensed medical dispensaries that possess the appropriate licensing will also be able to begin selling products to adult-only consumers.
However, only a handful of facilities are expected to be ready to engage in adult-use sales next month, the agency's director cautioned. Currently, 41 medical marijuana businesses have been pre-qualified to conduct retail sales.
Michigan voters approved a statewide initiative last year authorizing state officials to regulate the plant's production, use, and sale.
Report: Toxins Identified in the Vapor of Unregulated THC Vape Products
Van Nuys, CA: An analysis of the vapor produced by unregulated THC and/or CBD vape cartridges by the laboratory CannaSafe has identified the presence of pesticides, vitamin E acetate (oil), and other dangerous chemicals.
Investigators analyzed six vape cartridge products obtained on the illicit market and seven products purchased from legally regulated retailers.
All six of the illicitly produced products contained percentages of vitamin E oil exceeding 30 percent. Recently, the US Centers for Disease Control identified vitamin E acetate as a "very strong culprit of concern" in EVALI (e-cigarette or vaping product use-associated lung injury), and several states – such as Ohio and Washington – have banned the sale of vapor products from containing the additive.
Researchers also identified the presence of other cutting agents, such as propylene glycol, which can produce dangerous toxins when heated. In separate testing of the products' vapor content, investigators identified formaldehyde and hydrogen cyanide, along with various pesticides. Significantly elevated levels of lead were also detected in one of the products.
By contrast, testing performed on the vape products obtained at state-licensed facilities did not test positive for either vitamin E or other toxic chemicals.
Authors concluded: "In this report, CannaSafe was able to quantify harmful compounds and found them to make up a large portion of illicit cartridges whereas legal cartridges were clean. These findings further provide evidence that regulation is working, [and that] a ban would only force patients back into a dangerous and unregulated market, which would surely lead to more illness. We encourage all consumers to buy [only] legal products from licensed dispensaries."
Full text of the CannaSafe report appears online.
New Jersey: Senate Leaders Propose 2020 Legalization Ballot Measure
Trenton, NJ: Senate President Steve Sweeney and Sen. Nicholas Scutari, Chairman of the Senate Judiciary Committee, announced plans this week to place a constitutional amendment on the 2020 ballot to legalize and regulate adult cannabis use.
"This initiative will bring cannabis out of the underground so that it can be controlled to ensure a safe product, strictly regulated to limit use to adults, and have sales subjected to the sales tax," they said in a joint press release. "We will move forward with a plan that helps correct social and legal injustices that have had a discriminatory impact on communities of color. We can make real progress toward social justice at the same time cannabis is made safe and legal."
According to a statewide Monmouth University poll released this year, 62 percent of New Jersey adults support legalizing personal use quantities of cannabis and 80 percent approve of it being sold at licensed retail outlets.
Legislative efforts to enact a system of regulated marijuana sales stalled after the proposal failed to obtain sufficient support to pass a Senate floor vote.